English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: Ipilimumab is an antibody for the treatment of metastatic melanoma that currently is scarcely accessible for most cancer centers in Mexico, and this is why a descriptive analysis was carried out in the ABC Hospital, with this being one of the few centers that use this drug in the entire country. Material and methods: A three-year observational study was carried out with the general purpose to describe the clinical course of ipilimumabtreated patients and with the specific purpose to perform an overall survival analysis. Demographic, diagnostic, therapeutic, and clinical variables were analyzed. The response was assessed according to Wolchok’s immune response criteria. Results: Thirteen patients were included, out of which 53% (7/13) were females and 46% (6/13) males, with a median age of 54 years at diagnosis. Median total follow-up of the population was 18 months, and all patients were treated with ipilimumab 3 mg/kg every three weeks for four sessions. Overall survival and progression-free survival had a median of 18 (IQR: 8-24) and 5 (IQR: 4-24) months, respectively. Conclusions: In this cross-sectional cohort analysis, observations on metastatic or recurrent melanoma treatment with ipilimumab published up to now were corroborated. With a response rate of 23%, an essential outcome is a response duration of more than 28 months until current follow-up of the patients who show an objective response with the use of ipilimumab. (creativecommons.org/licenses/by-nc-nd/4.0/). *E-mail for correspondence: dr.camacholimas@gmail.com (C.P. Camacho-Limas) ORIGINAL ARTICLE Use of Ipilimumab in Patients Diagnosed with Metastatic Melanoma: Three-Year Experience in a Private Hospital in Mexico City Christian Patricio Camacho-Limas1,*, Guillermo Olivares-Beltrán1, Raquel Gerson-Cwilich2, Alberto Villalobos-Prieto1, María del Ángel Góngora-Jurado3 and Alain Sánchez-Rodríguez4 1Department of Medical Oncology, 2Cancer Center, 3Clinical Pathology, and 4Internal Medicine, Centro Médico ABC, Mexico City, Mexico Received for publication: 31 August 2016; accepted for publication: 25 February 2017 Available online: 14 July 2017